Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 694

1.

Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction.

Leite S, Cerqueira RJ, Ibarrola J, Fontoura D, Fernández-Celis A, Zannad F, Falcão-Pires I, Paulus WJ, Leite-Moreira AF, Rossignol P, López-Andrés N, Lourenço AP.

Circ Heart Fail. 2019 Jul;12(7):e005596. doi: 10.1161/CIRCHEARTFAILURE.118.005596. Epub 2019 Jul 1.

PMID:
31525070
2.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators.

Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1596. [Epub ahead of print]

PMID:
31523904
3.

Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial.

Ferreira JP, Rossello X, Pitt B, Rossignol P, Zannad F.

Clin Cardiol. 2019 Sep 3. doi: 10.1002/clc.23261. [Epub ahead of print]

4.

Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure.

Coiro S, Girerd N, Sharma A, Rossignol P, Tritto I, Pitt B, Pfeffer MA, McMurray JJV, Ambrosio G, Dickstein K, Moss A, Zannad F.

Eur J Heart Fail. 2019 Sep 2. doi: 10.1002/ejhf.1541. [Epub ahead of print]

PMID:
31476097
5.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees.

N Engl J Med. 2019 Sep 1. doi: 10.1056/NEJMoa1908655. [Epub ahead of print]

PMID:
31475794
6.

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B.

Eur Heart J. 2019 Jun 25. doi: 10.1093/eurheartj/ehz427. [Epub ahead of print]

PMID:
31461239
7.

World Heart Federation Roadmap for Heart Failure.

Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H, Lam CSP, Martinez-Rubio A, McMurray JJV, Mebazaa A, Panjrath G, Piña IL, Sani M, Sim D, Walsh M, Yancy C, Zannad F, Sliwa K.

Glob Heart. 2019 Sep;14(3):197-214. doi: 10.1016/j.gheart.2019.07.004. No abstract available.

PMID:
31451235
8.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA.

Lancet. 2019 Aug 22. pii: S0140-6736(19)31792-1. doi: 10.1016/S0140-6736(19)31792-1. [Epub ahead of print]

PMID:
31447116
9.

Heart failure around the world.

Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam CSP.

Eur J Heart Fail. 2019 Aug 16. doi: 10.1002/ejhf.1585. [Epub ahead of print]

PMID:
31419004
10.

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.

Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators.

JACC Heart Fail. 2019 Jul 10. pii: S2213-1779(19)30409-3. doi: 10.1016/j.jchf.2019.05.015. [Epub ahead of print]

PMID:
31302043
11.

Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.

Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, Solomon SD, Dickstein K, Atar D, Agewall S, Girerd N; High-Risk Myocardial Infarction Database Initiative investigators.

Am Heart J. 2019 Sep;215:83-90. doi: 10.1016/j.ahj.2019.06.004. Epub 2019 Jun 12.

PMID:
31291604
12.

Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study.

Kobayashi M, Bercker M, Huttin O, Pierre S, Sadoul N, Bozec E, Chouihed T, Ferreira JP, Zannad F, Rossignol P, Girerd N.

Int J Cardiol. 2019 Jun 26. pii: S0167-5273(19)30635-7. doi: 10.1016/j.ijcard.2019.06.062. [Epub ahead of print]

PMID:
31281047
13.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2019 Jul 1. doi: 10.1007/s00392-019-01513-y. [Epub ahead of print]

PMID:
31263996
15.

Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963-972].

Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD.

Eur J Heart Fail. 2019 Jun;21(6):819. doi: 10.1002/ejhf.1480. Epub 2019 May 9. No abstract available.

PMID:
31222927
16.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986
17.

Association Between Layer-Specific Longitudinal Strain and Risk Factors of Heart Failure and Dyspnea: A Population-Based Study.

Huttin O, Girerd N, Coiro S, Bozec E, Selton-Suty C, Lamiral Z, Frikha Z, Kobayashi M, Argulian E, Narula J, Fraser AG, Rossignol P, Zannad F.

J Am Soc Echocardiogr. 2019 Jul;32(7):854-865.e8. doi: 10.1016/j.echo.2019.03.011. Epub 2019 May 16.

PMID:
31104890
18.

Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, Butler J, Clark A, Cleland JG, Delles C, Diez J, Girerd N, González A, Hazebroek M, Huby AC, Jukema W, Latini R, Leenders J, Levy D, Mebazaa A, Mischak H, Pinet F, Rossignol P, Sattar N, Sever P, Staessen JA, Thum T, Vodovar N, Zhang ZY, Heymans S, Zannad F.

Circ Heart Fail. 2019 May;12(5):e005897. doi: 10.1161/CIRCHEARTFAILURE.118.005897.

PMID:
31104495
19.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Aug;21(8):965-973. doi: 10.1002/ejhf.1482. Epub 2019 May 14.

PMID:
31087601
20.

Estimated Long-Term Survival With Eplerenone.

Stienen S, Ferreira JP, Vincent J, Busselen M, Li B, McMurray JJV, Pitt B, Girerd N, Rossignol P, Zannad F.

J Am Coll Cardiol. 2019 May 14;73(18):2357-2359. doi: 10.1016/j.jacc.2019.02.043. No abstract available.

PMID:
31072582
21.

Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses.

Ferreira JP, Pizard A, Machu JL, Bresso E, Rocca HB, Girerd N, Leroy C, González A, Diez J, Heymans S, Devignes MD, Rossignol P, Zannad F; FIBRO-TARGETS investigators.

Clin Res Cardiol. 2019 May 6. doi: 10.1007/s00392-019-01480-4. [Epub ahead of print]

PMID:
31062082
22.

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.

Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F.

JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049.

PMID:
31017637
23.

Low fibrosis biomarker levels predict cardiac resynchronization therapy response.

Massoullié G, Sapin V, Ploux S, Rossignol P, Mulliez A, Jean F, Marie PY, Merlin C, Pereira B, Andronache M, Motreff P, Chabin X, Sellal JM, Citron B, Lusson JR, Vorilhon C, Clerfond G, Bordachar P, Zannad F, Eschalier R.

Sci Rep. 2019 Apr 15;9(1):6103. doi: 10.1038/s41598-019-42468-4.

24.

The continuous heart failure spectrum: moving beyond an ejection fraction classification.

Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, Bauersachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW.

Eur Heart J. 2019 Jul 1;40(26):2155-2163. doi: 10.1093/eurheartj/ehz158.

PMID:
30957868
25.

Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative.

Stienen S, Ferreira JP, Girerd N, Duarte K, Lamiral Z, McMurray JJV, Pitt B, Dickstein K, Zannad F, Rossignol P; High-Risk Myocardial Infarction Database Initiative.

Clin Res Cardiol. 2019 Apr 5. doi: 10.1007/s00392-019-01453-7. [Epub ahead of print]

PMID:
30953180
26.

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.

Rossignol P, Frimat L, Zannad F.

Kidney Int. 2019 Apr;95(4):747-749. doi: 10.1016/j.kint.2018.12.006.

PMID:
30904064
27.

Heart failure drug treatment.

Rossignol P, Hernandez AF, Solomon SD, Zannad F.

Lancet. 2019 Mar 9;393(10175):1034-1044. doi: 10.1016/S0140-6736(18)31808-7. Review.

PMID:
30860029
28.

Rivaroxaban in Patients with Heart Failure. Reply.

Zannad F, Greenberg B, Fu M.

N Engl J Med. 2019 Mar 7;380(10):988-989. doi: 10.1056/NEJMc1816756. No abstract available.

PMID:
30855759
29.

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments.

Zannad F, Ferreira JP, Pitt B.

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A55-A60. doi: 10.1093/eurheartj/suy034. Epub 2019 Feb 26.

30.

Is Sacubitril/Valsartan Antifibrotic?

Zannad F, Ferreira JP.

J Am Coll Cardiol. 2019 Feb 26;73(7):807-809. doi: 10.1016/j.jacc.2018.11.041. No abstract available.

PMID:
30784674
31.

Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure.

Kobayashi M, Watanabe M, Coiro S, Bercker M, Paku Y, Iwasaki Y, Chikamori T, Yamashina A, Duarte K, Ferreira JP, Rossignol P, Zannad F, Girerd N.

Int J Cardiol. 2019 Aug 15;289:91-98. doi: 10.1016/j.ijcard.2019.01.091. Epub 2019 Feb 8.

PMID:
30770263
32.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
33.

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.

Januzzi J, Ferreira JP, Böhm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.

PMID:
30767353
34.

Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study).

Lopez-Sublet M, Girerd N, Bozec E, Machu JL, Ferreira JP, Zannad F, Mourad JJ, Rossignol P.

Am J Hypertens. 2019 Jun 11;32(7):620-628. doi: 10.1093/ajh/hpz020.

PMID:
30753257
35.

Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis.

Dewan P, Rørth R, Jhund PS, Ferreira JP, Zannad F, Shen L, Køber L, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators.

JACC Heart Fail. 2019 Apr;7(4):336-346. doi: 10.1016/j.jchf.2018.11.005. Epub 2019 Feb 6.

36.

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.

de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, Du XJ, Ford P, Heinzel FR, Lipson KE, McDonagh T, Lopez-Andres N, Lunde IG, Lyon AR, Pollesello P, Prasad SK, Tocchetti CG, Mayr M, Sluijter JPG, Thum T, Tschöpe C, Zannad F, Zimmermann WH, Ruschitzka F, Filippatos G, Lindsey ML, Maack C, Heymans S.

Eur J Heart Fail. 2019 Mar;21(3):272-285. doi: 10.1002/ejhf.1406. Epub 2019 Feb 4.

37.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jul;108(7):797-805. doi: 10.1007/s00392-018-1409-x. Epub 2019 Jan 4.

38.

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.

Chin KL, Collier T, Pocock S, Pitt B, McMurray JJV, van Veldhuisen DJ, Swedberg K, Vincent J, Zannad F, Liew D.

Clin Res Cardiol. 2019 Jul;108(7):806-814. doi: 10.1007/s00392-018-1410-4. Epub 2019 Jan 2.

39.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
40.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.

Zannad F, Rossignol P.

Circulation. 2019 Jan 15;139(3):362-365. doi: 10.1161/CIRCULATIONAHA.118.038399. No abstract available.

PMID:
30586788
41.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
42.

Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.

Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA.

Int J Cardiol. 2018 Nov 15;271:132-139. doi: 10.1016/j.ijcard.2018.04.001. Epub 2018 Jul 7.

43.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
44.

Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study.

Ferreira JP, Bauters C, Eschalier R, Lamiral Z, Fay R, Huttin O, Girerd N, Zannad F, Pinet F, Rossignol P.

ESC Heart Fail. 2019 Feb;6(1):70-79. doi: 10.1002/ehf2.12359. Epub 2018 Nov 20.

45.

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Cosentino F, Ceriello A, Baeres FMM, Fioretto P, Garber A, Stough WG, George JT, Grant PJ, Khunti K, Langkilde AM, Plutzky J, Rydén L, Scheen A, Standl E, Tuomilehto J, Zannad F.

Eur Heart J. 2019 Sep 7;40(34):2907-2919. doi: 10.1093/eurheartj/ehy677. No abstract available.

PMID:
30445605
46.

Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.

Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Böhm M, Maggioni AP, Lewis EF, Zannad F, Butler J.

Eur J Heart Fail. 2018 Dec;20(12):1760-1763. doi: 10.1002/ejhf.1310. Epub 2018 Nov 11. No abstract available.

PMID:
30415473
47.

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.

Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL.

Clin Proteomics. 2018 Nov 2;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018.

48.

Correction to: Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.

Kobayashi M, Rossignol P, Ferreira JP, Aragão I, Paku Y, Iwasaki Y, Watanabe M, Fudim M, Duarte K, Zannad F, Girerd N.

Clin Res Cardiol. 2019 May;108(5):562. doi: 10.1007/s00392-018-1390-4.

PMID:
30402715
49.

Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.

White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP.

J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

50.

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF.

Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, Ng LL.

Eur J Heart Fail. 2019 Jul;21(7):877-886. doi: 10.1002/ejhf.1338. Epub 2018 Oct 29.

PMID:
30370976

Supplemental Content

Loading ...
Support Center